Sun X F, Ekberg H, Zhang H, Carstensen J M, Nordenskjöld B
Department of Oncology, Linköping University, Sweden.
APMIS. 1998 Jun;106(6):657-64.
The expression of ras was investigated by using immunohistochemistry in 245 primary colorectal adenocarcinomas and 49 corresponding metastases in the lymph nodes. One hundred and forty-four (59%) of the primary tumours presented as ras positive and 37 (76%) were positive in metastases. The ras expression was positively related to cell proliferation (p=0.01) and significantly increased in tumours with aneuploidy (68%) compared to tumours with diploidy (51%) and tetraploidy (53%, p=0.01). The frequency of ras expression was increased from Dukes' stage A to stages B-D (41% vs 62%, p=0.01). ras expression was compared in 40 paired primary tumours and their corresponding metastases, and the difference in expression did not reach statistical significance (73% vs 83%, p=0.32). In survival analyses, ras overexpression predicted a poor prognosis independent of Dukes' stage, DNA ploidy and S-phase fraction (p=0.049). We did not find any significant relationship between ras expression and patients' sex, age, tumour location, growth pattern, differentiation, p53 expression or heat shock protein. The results indicate that the alteration of ras expression may be involved in the instability of DNA and cellular overproliferation, but not in the progression to advanced stage and the development of metastases. The expression of ras was an important biological marker for evaluating the prognosis in patients with colorectal adenocarcinoma.
采用免疫组织化学方法对245例原发性大肠腺癌及其49例相应的淋巴结转移癌进行了ras表达情况的研究。144例（59%）原发性肿瘤表现为ras阳性，37例（76%）转移癌为阳性。ras表达与细胞增殖呈正相关（p=0.01），与二倍体肿瘤（51%）和四倍体肿瘤（53%）相比，非整倍体肿瘤中ras表达显著增加（68%，p=0.01）。ras表达频率从Dukes分期A期到B - D期呈增加趋势（41%对62%，p=0.01）。对40对原发性肿瘤及其相应转移癌的ras表达进行比较，表达差异无统计学意义（73%对83%，p=0.32）。在生存分析中，ras过表达预示预后不良，且独立于Dukes分期、DNA倍体和S期分数（p=0.049）。我们未发现ras表达与患者性别、年龄、肿瘤部位、生长方式、分化程度、p53表达或热休克蛋白之间存在任何显著关系。结果表明，ras表达改变可能参与DNA的不稳定性和细胞过度增殖，但不参与进展至晚期和转移的发生。ras表达是评估大肠腺癌患者预后的重要生物学标志物。
